Form 4: Immunovant Director Douglas J. Hughes Reports Acquisition of Shares and Stock Options

Director Douglas J. Hughes reported the acquisition of 11,255 restricted stock units and 4,690 stock options in Immunovant, Inc. on April 2, 2024.

Summary

• On April 2, 2024, Douglas J. Hughes, a director of Immunovant, Inc., acquired 11,255 restricted stock units (RSUs) and 4,690 stock options.
• The RSUs were granted under the Issuer's 2019 Equity Incentive Plan and represent a contingent right to receive one share of common stock upon vesting.
• The RSUs will vest in full on April 2, 2025, contingent upon Hughes' continuous service to the Issuer.
• Hughes may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A requirements.
• The stock options, with an exercise price of $30.78, also vest on April 2, 2025, subject to continuous service.
• Following these transactions, Hughes beneficially owns 125,010 shares of common stock and 4,690 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants to a director. The vesting schedule and exercise price are typical.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
• The vesting requirements tied to continuous service align the director's interests with those of the shareholders.

Future Outlook

The vesting of the RSUs and stock options on April 2, 2025, is contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. These filings are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates